Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02367066
- Testing
- AR-C165395XX
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone.
- Trial name
- NCT01095666
- Testing
- Dapagliflozin, Metformin, Pioglitazone
- Where
- 33 sites in China, India and 1 more
- Volunteers
- 1,484 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector…
- Trial name
- NCT04001231
- Testing
- Exenatide Once-Weekly Suspension
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
- Trial name
- NCT03362112
- Volunteers
- 1,713 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
This is an open-labeled, randomized, multicenter, prospective, parallel group, interventional study to demonstrate the effectiveness of 24 weeks treatment with Vildagliptin 50mg bid as add on to metformin 500 mg bid compared to…
- Trial name
- NCT01541956
- Testing
- Metformin, vildagliptin
- Where
- China
- Volunteers
- 3,091 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus Type 2
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct…
- Trial name
- NCT02205528
- Testing
- Liraglutide, Metformin, NNC0090-2746
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novo Nordisk A/S
Resistant Hypertension, NIDDM
Resistant Hypertension in Patients With Type-II-Diabetes Mellitus
The risk of cardiovascular disease (CVD) in patients with type-II-diabetes mellitus (type-II-DM)is more than doubled and CVD accounts for 70% of deaths in this group of patients.
- Trial name
- RESIST (NCT01056367)
- Where
- Denmark
- Volunteers
- 180 people
- Sponsor
- Svendborg Hospital
Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.
- Trial name
- NCT05659537
- Testing
- Dulaglutide
- Where
- 7 sites in India
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
- Trial name
- AWARD-11 (NCT03495102)
- Testing
- Dulaglutide
- Where
- 208 sites in United States, Argentina and 14 more
- Volunteers
- 1,842 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Effectiveness of Motivational Interviewing on Improving Care for Patients With Type 2 Diabetes in China
n 2015, the International Diabetes Federation estimated that there were nearly 110 million diabetes mellitus (DM) patients in China, which was the highest number recorded in the world.
- Trial name
- NCT04342845
- Volunteers
- 225 people
- Sponsor
- The University of Hong Kong
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Type 2 Diabetes Mellitus (T2DM)
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet…
- Trial name
- HDNO-1605 (NCT06647550)
- Testing
- HD-6277 100mg, HD-6277 50mg, HD-6277 25mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Hyundai Pharm
Type2 Diabetes
Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes
Investigation of the anatomical distribution of enteroendocrine cells by a systematic approach along the entire human intestinal tract in healthy individuals and patients with type 2 diabetes.
- Trial name
- NCT03044860
- Testing
- Double-balloon enteroscopy (DBE) with biopsy retrieval
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus Type II, Acute Coronary Syndrome
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
The purpose of this study is to determine if, in type 2 diabetic patients undergoing treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a loading dose of 60 mg of prasugrel followed by 10 mg once…
- Trial name
- VERDI (NCT01684813)
- Testing
- Prasugrel., Clopidogrel
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Type 2 Diabetes, Healthy
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin sensitivity in skeletal muscle, liver, and fat cells.
- Conditions
- Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
- Trial name
- PIO-EX (NCT00845182)
- Testing
- Pioglitazone, Exenatide, Pioglitazone and Exenatide
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type-2 Diabetes Mellitus, Coronary Artery Disease
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes.
- Trial name
- NCT01823510
- Testing
- Ticagrelor + Aspirin, Clopidogrel + Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan J Badimon
Depression, Postpartum
Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine
Type 2 Diabetes (T2DM) is a life-long, chronic condition affecting an individuals' ability to regulate glucose levels in the blood. Diabetes can cause many severe complications if not treated properly.
- Trial name
- NCT01602913
- Testing
- Pravastatin alone, Paroxetine alone, Pravastatin and paroxetine combined
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Pancreatectomy, Diabetes Mellitus Type 2
Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients
This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.
- Conditions
- Pancreatectomy, Diabetes Mellitus Type 2, Pancreatic Neoplasms
- Trial name
- DCP-NDM (NCT07608055)
- Where
- Italy
- Volunteers
- 579 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS